Articles On TBG Diagnostics (ASX:TDL)

It was a positive start to the week for the Australian bourse. The ASX 200 rose 0.22% to 7,505 while the ASX Emerging Companies Index gained nearly 2% and closed at 2,331 – a two week high following a 6% drop in the week before last. The ga...

One of the inconveniences of COVID-19 tests is that they can take several hours to complete. A number of ASX stocks are attempting to create faster tests, including two that surged this morning. AnteoTech Ltd (ASX:ADO), which said it has es...

Two COVID-19 antibody kits have failed post-market testing, raising more questions about the 20 point-of-care kits approved for sale in Australia. Four of the 20 point-of-care tests (PoCT) available in Australia have now failed independent...

As could be expected, the molecular diagnostics house’s announcement of European approval of its Chinese investee company’s COVID-19 test was greeted with a powerful share rally. The trouble is, some investors appear to have developed psych...

It’s tough to sell anything in a foreign market if you can’t even get out of your home market, and that’s a dilemma now faced by TBG Diagnostics (ASX:TDL). The company’s Chinese investee, TBG Biotechnology Xiamen, has a kit which it says ca...

The market for COVID-19 diagnostic kits is much broader than just the health sector, as miners and other industries begin to compete for tests with governments. But where diagnostic tests normally require at minimum several months of patien...

Despite March being a tough month to raise capital for ASX small caps, the money was still flowing for the gold explorers. In March, ASX small caps raised $72.2m, a steep decline from the $125m raised in February. Even in January, tradition...

Before 1942, Australia hadn’t fully come to terms with what a world war would require it to do. By the end of 1942, after the Japanese Imperial airforce bombed Darwin, the country was a very different place. It had gone from a tiny populati...

Each Monday, Stockhead recaps which stocks are most heavily in demand by investors — running hot. The analysis is based on the Relative Strength Index (RSI), a technical gauge which measures how trading momentum is affecting the price actio...

The ASX is cracking down on biotech and health companies disclosures around possible coronavirus-linked products. Yesterday TBG Diagnostics (ASX:TDL) was suspended as the ASX looks into why it waited until Wednesday to reveal that a COVID19...

The corporate watchdog is examining suspicious trading in TBG Diagnostics Limited after its shares jumped 800pc.

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks, only nine were in positive territory over the last fortnight; nine were flat and 119 saw their share prices fall. Cod...

We now know why TBG Diagnostics (ASX:TDL) shares more than doubled this week: it has European approval for its COVID-19 testing kit. The company’s Chinese investee received CE approval for a nucleic acid diagnostics kit for COVID-19, meanin...

Melbourne-based biotech firm TBG Diagnostics Ltd [ASX:TDL] (formerly Progen Pharmaceuticals Ltd) saw a massive jump in its share price during trade yesterday. The maker of molecular diagnostic kits jumped a whopping 438% The post Why Did th...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks, 112 saw their share prices fall, 17 improved and eight were flat. Code Name Price $ (March 3) 2 week return %...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...